ProCE Banner Activity

Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients

Slideset Download
Conference Coverage
Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.

Released: December 14, 2017

Expiration: December 13, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation